A newly FDA approved procedure has the power to save children from a painful cornea transplant. Keratoconus presents in about 1:2000, with a high prevalence in the Down Syndrome population. The disease causes the cornea to become thin and bulge. Corneal crosslinking improves the connections among the membranes of the cornea by a factor of four, preventing the need for a cornea transplant. Erin Stahl, MD is here to explain that Children’s Mercy Kansas City provided one of the first FDA-approved pediatric treatments in February 2017, providing new hope for Keratoconus.